Matthew Barcus
Stock Analyst at Chardan Capital
(2.43)
# 2,459
Out of 5,122 analysts
21
Total ratings
25%
Success rate
29.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $5.35 | +86.92% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $24.56 | +9.93% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $7 | $0.65 | +976.92% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $25.61 | +24.95% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $220 | $0.68 | +32,381.91% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $3.18 | +183.02% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $21.60 | -62.96% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $5.35
Upside: +86.92%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $24.56
Upside: +9.93%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $7
Current: $0.65
Upside: +976.92%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $25.61
Upside: +24.95%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $220
Current: $0.68
Upside: +32,381.91%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $3.18
Upside: +183.02%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $21.60
Upside: -62.96%